Table 2.
Univariate analyses of prognostic factors for disease-free survival and overall survival of patients with stage III colon cancer
| Variable | Disease-free survival | Overall survival | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (> 60 years vs. ≤ 60 years) | 1.401 (0.804–2.443) | 0.234 | 1.390 (0.661–2.925) | 0.385 |
| Sex (male vs. female) | 1.943 (1.081–3.494) | 0.026 | 1.902 (0.871–4.154) | 0.107 |
| BMI(< 18.5 kg/m2 vs. ≥ 18.5 kg/m2) | 0.760 (0.274–2.107) | 0.598 | 1.892 (0.724–4.944) | 0.193 |
| Hemoglobin (< 90 g/L vs. ≥ 90 g/L) | 0.965 (0.455–2.047) | 0.926 | 0.818 (0.285–2.346) | 0.709 |
| Tumor location (right-sided colon vs. left-sided colon) | 1.356 (0.787–2.334) | 0.272 | 2.243 (1.089–4.619) | 0.028 |
| Tumor size (> 4 cm vs. ≤ 4 cm) | 0.941 (0.548–1.613) | 0.824 | 1.046 (0.511–2.140) | 0.902 |
| Differentiation (poor vs. well/moderate) | 1.143 (0.621–2.106) | 0.667 | 1.181 (0.525–2.656) | 0.687 |
| T stage (T4 vs. T1–3) | 1.553 (0.890–2.708) | 0.121 | 1.709 (0.797–3.668) | 0.169 |
| N stage (N2 vs. N1) | 1.573 (0.907–2.729) | 0.107 | 1.487 (0.716–3.089) | 0.287 |
| CEA (> 5 ng/mL vs. ≤ 5 ng/mL) | 1.557 (0.908–2.671) | 0.107 | 0.987 (0.479–2.034) | 0.972 |
| Adjuvant chemotherapy (6–8 cycles vs. < 6 cycles) | 0.590 (0.320–1.087) | 0.091 | 0.308 (0.148–0.640) | 0.002 |
| LMR (> 4.00 vs. ≤ 4.00) | 0.840 (0.488–1.447) | 0.530 | 0.759 (0.365–1.578) | 0.460 |
| NLR (> 2.05 vs. ≤ 2.05) | 0.915 (0.534–1.568) | 0.746 | 0.872 (0.425–1.789) | 0.708 |
| PLR (> 142.99 vs. ≤ 142.99) | 1.067 (0.622–1.831) | 0.812 | 1.091 (0.533–2.237) | 0.811 |
| PNI (≤ 49.22 vs. > 49.22) | 1.889 (1.094–3.262) | 0.023 | 2.353 (1.118–4.950) | 0.024 |
HR hazard ratio, CI confidence interval, BMI body mass index, CEA carcinoembryonic antigen, LMR lymphocyte-to-monocyte ratio, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, PNI prognostic nutritional index